Success Metrics

Active Trials
1(20%)

Phase Distribution

Ph not_applicable
1
20%
Ph early_phase_1
2
40%
Ph phase_2
1
20%
Ph phase_1
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
2(40.0%)
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Other(4)

Detailed Status

unknown4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (40.0%)
Phase 11 (20.0%)
Phase 21 (20.0%)
N/A1 (20.0%)

Trials by Status

active_not_recruiting120%
unknown480%

Recent Activity

1 active trials
Showing 5 of 5
unknownphase_2

CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

NCT06078306
unknownnot_applicable

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05797948
active_not_recruitingphase_1

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

NCT04499573
unknownearly_phase_1

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

NCT04626726
unknownearly_phase_1

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

NCT04626739

Clinical Trials (5)

Showing 5 of 5 trials
NCT06078306Phase 2

CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

Unknown
NCT05797948Not Applicable

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Unknown
NCT04499573Phase 1

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

Active Not Recruiting
NCT04626726Early Phase 1

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Unknown
NCT04626739Early Phase 1

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5